Chemotherapy Compounding Events 
European Pharmaceutical Review
OCTOBER 25, 2024
The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings.
Pharmaceutical Technology
APRIL 4, 2023
Ivospemin is a subcutaneously administered polyamine analogue being developed by Panbela to induce polyamine metabolic inhibition (PMI) through the exploitation of an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumours.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 29, 2022
By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI. No serious adverse events were observed. g/kg of NT-I7) had completed recruitment in the NIT-112 study.
Pharmaceutical Technology
FEBRUARY 13, 2023
This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections.
Pharmacy Times
JUNE 13, 2025
Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.
The Checkup by Singlecare
MARCH 23, 2023
Understanding the difference between CBD vs. marijuana Cannabinoids are compounds found in the cannabis plant, Cannabis sativa. By inhibiting CYP3A4, CBD/THC can increase patients’ exposure to these medications, increasing the risk of toxicity and adverse events. Marijuana , also called cannabis, contains more than 100 cannabinoids.
Pharmacy Times
JUNE 25, 2025
Safety profiles were manageable, with similar rates of grade 3 or higher adverse events between the treatment groups. months versus 7.79 months with tislelizumab. months versus 7.79 months with tislelizumab. months versus 7.79 months with tislelizumab. The overall response rate was higher in the benmelstobart group at 71.9% compared to 65.1%
Expert insights. Personalized for you.
97 
Let's personalize your content